Servier acquires non-Hodgkin B-cell lymphoma treatment PIXUVRI® (pixantrone) from CTI BioPharma, strengthening the Servier oncology portfolio

Servier, an independent international pharmaceutical company, today announced the acquisition of PIXUVRI® from CTI BioPharma.

Servier, an independent international pharmaceutical company, today announced the acquisition of PIXUVRI® from CTI BioPharma. PIXUVRI is a treatment for adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma. Servier and CTI Biopharma completed an Asset Purchase Agreement which transferred worldwide rights of PIXUVRI to Servier. Servier commercialized PIXUVRI globally, in all countries where the drug was approved under an exclusive license from CTI BioPharma.

 

“The acquisition of PIXUVRI is an important step towards Servier’s long-term strategy to become a key player in oncology. Within oncology, one of our key focuses is hematology, and we now have two medicines that are marketed globally alongside a strong and innovative pipeline of drug candidates which includes CAR-T therapies,” said Claude Bertrand, Executive VP, Global Head of R&D at Servier. “As part of our strategy, we are committed to invest 50% of our R&D budget in oncology.”

 

Non-Hodgkin lymphoma (NHL) is a blood cancer that affects the lymphatic system, it can occur in different parts of the body from the lymph nodes in the neck to the liver or spleen, but also in other organs such as the stomach, small bowel, bones, brain, testicles or skin.1 Globally there are over 500,000 new cases of NHL a year; it is both the 11th most commonly diagnosed cancer and cause of cancer death.2

 

“We have a strong commitment to providing effective solutions for patients living with cancer. PIXUVRI is an effective treatment that received standard European marketing authorization in June, and today marks a new step towards achieving Servier’s long term goals. We will ensure that patients will continue to have access to PIXUVRI”, said Eric Falcand, VP, Global Head of Business Development & Licensing at Servier. “We are continuing to strengthen our oncology portfolio through our R&D efforts and strategic alliances.”

Tags : #servier #pixantrone #pixuvri #lymphoma #biopharma #technology #medicine #healthacare

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

The Hidden Dangers of Scented Candles: Aesthetic Bliss or Silent Health Hazard?February 18, 2025
The University of Leeds and Sri Balaji Vidyapeeth Host 3rd International Health and Research Convention to Advance Global Healthcare and Medical ResearchFebruary 17, 2025
When ‘You Don’t Look Sick’ Becomes a Death Sentence for Chronic Illness PatientsFebruary 17, 2025
7 Essential Tips for Keeping Your Liver HealthyFebruary 17, 2025
Apollo Hospitals to Host International Health Dialogue 2025 in New Delhi: A Global Summit on Patient Safety & Digital InnovationFebruary 17, 2025
Distractions significantly delay remote drivers’ reaction timeFebruary 17, 2025
Narayana Health SRCC Children's Hospital, Mumbai Observes International Childhood Cancer Day with Muskan Ki Mehfil—A Tribute to Courage and HopeFebruary 17, 2025
Eating from Plastic Containers? You Might Be Ingesting a Heart AttackFebruary 17, 2025
Lost Memories? Scientists Uncover the Mysterious Neurons That Could Save Your BrainFebruary 17, 2025
Lost Memories? Scientists Uncover the Mysterious Neurons That Could Save Your BrainFebruary 17, 2025
When the Mind Hurts, the Body Follows: How Depression Creates Havoc on Physical HealthFebruary 14, 2025
The Creativity Paradox: How Losing Control of Your Mind Can Set Your Imagination FreeFebruary 14, 2025
Why You Crave Sugar Even When You’re Stuffed: The Science Behind Sweet TemptationsFebruary 14, 2025
Why You Crave Sugar Even When You’re Stuffed: The Science Behind Sweet TemptationsFebruary 14, 2025
February 14, 2025
Rela Hospital Performs Advanced Endoscopic Breast Conservation Surgery for 60-Year-Old Cancer PatientFebruary 14, 2025
Assistive Technologies and Flexible Work Can Enhance Workforce Participation of Persons with Disabilities, Two New Reports FindFebruary 14, 2025
Pristyn Care Launches its First Super-speciality Hospital in South Delhi, Ushering in a New Era of Patient-centric HealthcareFebruary 14, 2025
The University of Manchester launches significant Scholarships for 2025 for Indian StudentsFebruary 13, 2025
February 13, 2025